Telitacicept Shows Deep, Durable Response in Myasthenia Gravis Phase 3 Analysis
VOR has more than doubled off its 52-week low of $6.5.
Summary
Vor Bio released a post hoc analysis from the Phase 3 trial of telitacicept in generalized myasthenia gravis, conducted by collaborator RemeGen in China. The data show 94% of participants achieved at least a 5-point MG-ADL improvement at Week 48, 42% reached minimal symptom expression (MSE), and once MSE was achieved, 86.7% of events were sustained at the next monthly assessment. Participants spent 83-85% of remaining follow-up in MSE. The depth of response increased over time, with up to 13-point MG-ADL improvements observed. Safety was consistent with prior reports. This follows the September 8 news that Vor Bio completed enrollment in UPSTREAM MG, its global Phase 3 trial of telitacicept for the same indication. The positive durability data strengthen the case for telitacicept's global regulatory prospects, though the results are from a China-based trial and the global trial is still ongoing. The company faces financial distress, with a going concern warning and material weakness disclosed in its latest 10-Q, making positive clinical data critical for its outlook.
At the time of this announcement, VOR was trading at $18.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.50 to $49.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.